• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma.

作者信息

Yılmaz İnsu, Çetin Gülden Paçacı, Arslan Bahar

机构信息

Division of Immunology and Allergy, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey.

Division of Immunology and Allergy, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey.

出版信息

J Allergy Clin Immunol Pract. 2022 Jul;10(7):1935-1936. doi: 10.1016/j.jaip.2022.04.017.

DOI:10.1016/j.jaip.2022.04.017
PMID:35809995
Abstract
摘要

相似文献

1
Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma.重度嗜酸性粒细胞性哮喘患者在生物制剂之间进行的抗IL5/IL5R转换
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1935-1936. doi: 10.1016/j.jaip.2022.04.017.
2
Reply to "Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma".对“重度嗜酸性粒细胞性哮喘患者生物制剂间抗IL5/IL5R转换”的回复
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1936. doi: 10.1016/j.jaip.2022.04.018.
3
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.靶向白细胞介素 5/白细胞介素 5 受体的生物制剂诱导的重度哮喘缓解：一项多中心真实世界研究的结果。
Int J Mol Sci. 2023 Jan 27;24(3):2455. doi: 10.3390/ijms24032455.
4
Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.在连续两种生物制剂治疗失败后对美泊利珠单抗有反应的重度嗜酸性粒细胞性过敏性哮喘
J Investig Allergol Clin Immunol. 2019 Feb;29(1):79-81. doi: 10.18176/jiaci.0340.
5
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.抗 IL-5/IL-5R 治疗重度哮喘反应的特征：临床缓解的特征。
Front Immunol. 2024 Jan 23;15:1343362. doi: 10.3389/fimmu.2024.1343362. eCollection 2024.
6
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.奥马珠单抗可作为严重哮喘中慢性口服皮质类固醇替代疗法。
Respir Med. 2019 Apr;150:51-62. doi: 10.1016/j.rmed.2019.02.003. Epub 2019 Feb 7.
7
Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma.回顾性评估和生物性哮喘反应评分揭示了重度哮喘患者转换生物制剂的路线图。
Ann Allergy Asthma Immunol. 2024 Jan;132(1):91-93. doi: 10.1016/j.anai.2023.08.006. Epub 2023 Aug 12.
8
Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R.在接受抗IL5/IL5R治疗的真实队列中对FEOS评分和超级应答者标准的评估。
Respir Med. 2023 May;211:107216. doi: 10.1016/j.rmed.2023.107216. Epub 2023 Mar 21.
9
Severe asthma: what is new in the new millennium.严重哮喘：新千年的新进展。
Curr Opin Allergy Clin Immunol. 2020 Apr;20(2):202-207. doi: 10.1097/ACI.0000000000000623.
10
Biologics in severe asthma: Which one, When and Where?重度哮喘中的生物制剂：哪一种、何时使用以及何处使用？
Clin Exp Allergy. 2021 Sep;51(9):1225-1228. doi: 10.1111/cea.13989. Epub 2021 Jul 26.

引用本文的文献

1
Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma.严重哮喘中从生物制剂初始选择到生物制剂间转换的生物治疗管理。
Tuberk Toraks. 2023 Mar;71(1):75-93. doi: 10.5578/tt.20239910.